RDD 2026 - Building analytical best practices for respiratory biologics

Building Analytical Best Practices for Respiratory Biologics: Applying Biological and Respiratory Analytics to Emerging Modalities

As biologics such as peptides, proteins, monoclonal antibodies, oligonucleotides and mRNA therapies continue to advance, their delivery via inhaled and nasal products presents unique analytical challenges. Successfully developing these complex therapies requires the integration of established biologics testing with respiratory drug delivery analytics. 

This presentation explores best practices for characterising respiratory biologics, including the assessment of aggregation, oxidation, deamidation, potency and delivery stability. It also examines the challenges associated with aerosol performance testing, biologic recovery from impactors and testing equipment, and the development of robust analytical strategies to support product development. 

Featuring case studies with molecules including insulin, bovine serum albumin (BSA) and semaglutide, the presentation provides practical insights into analytical approaches for emerging inhaled biologic therapies. 

Download your copy of the presentation, "Building Analytical Best Practices for Respiratory Biologics", now.